 |
[Alpha Biz=(Chicago) Reporter Paul Lee] SK Bioscience's COVID-19 vaccine 'SKYCovione' was listed on the World Health Organization (WHO) Emergency Use List (EUL) following the UK official item license.
SK Bioscience announced on the 19th that its own COVID-19 vaccine SKYCovione has been listed on the WHO emergency use list.
SKYCovione is a COVID-19 vaccine jointly developed by SK Bioscience with the Institute for Antigen Design (IPD) of the University of Washington, USA, and GSK's immune booster is applied to strengthen immune response and induce neutralizing antibodies.
SKYCovione is used in flu vaccines and has been developed in a synthetic antigen method that has proven long-term safety and can be stored and distributed in refrigerated conditions of 2 to 8 degrees. This feature is seen as an advantage that will contribute to resolving the imbalance in vaccine supply highlighted by the pandemic.
Prior to this, SKYCovione already received official item approval last month for basic inoculation (primary and secondary) for adults aged 18 or older by the British Pharmaceutical and Health Care Products Regulatory Agency (MHRA), which is difficult for drug approval, along with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). SKYCovione is the first vaccine developed in Korea that has been officially licensed in the U.K.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
